Bernard Coulie Acquires Shares in Septerna, Inc.

Bernard Coulie, an insider at Septerna, Inc., recently purchased 15,000 shares of the company's stock. The transaction, which took place on June 26, was not part of a pre-planned trading plan. As of Wednesday, shares of Septerna, Inc. (NasdaqGM:SEPN) were trading at $34.75.

Insider Buying and Selling at Septerna, Inc.

In addition to Bernard Coulie's purchase, other notable insider transactions include Samira Shaikhly, the Chief People Officer, who sold 2,178 shares at $35.18 on June 29 under a Rule 10b5-1 plan. On the same day, Shaikhly also bought 2,178 shares at $6.81 outside of a planned sale. These transactions reflect a mix of planned and unplanned insider activity.

Other Institutional Activity in Septerna, Inc.

RA Capital Management, L.P. maintained its holding in Septerna, Inc. with 6,995,858 shares valued at approximately $168.1 million. Driehaus Capital Management LLC reduced its position by 413,898 shares, bringing its total to 4,395,572 shares worth about $105.6 million, an 8.6% decrease. Meanwhile, Goldman Sachs Group Inc. increased its holdings by 191,298 shares, ending with 2,906,427 shares valued at nearly $69.8 million, marking a 7.0% increase.

Septerna, Inc. Stock Down 12.2%

Septerna, Inc. operates in the biotechnology sector, focusing on G protein-coupled receptor therapies. As of Wednesday, the company had a market capitalization of approximately $1.68 billion. The stock's 52-week range spans from $10.3 to $37.99, with a 50-day moving average of $28.91 and a 200-day moving average of $25.31. Despite a negative EPS, the forward P/E ratio stands at -14.04, indicating the company is not currently profitable. Septerna maintains a strong liquidity position with a current ratio of 4.71 and a quick ratio of 4.63.

Recent Earnings

In its most recent earnings report, Septerna, Inc. posted revenue of $72.26 million, showcasing a remarkable growth of 120.11%. However, the company reported a net margin of -49.88% and a return on equity of -9.26%. The next earnings announcement is scheduled for August 10, 2026.

Analysts Set New Price Targets

Analyst sentiment remains positive, with Raymond James maintaining a 'buy' rating and a price target of $53 as of June 8, 2026. Other firms like JP Morgan and Truist Securities also uphold 'buy' ratings, with targets at $38 and $35, respectively. The consensus among nine analysts suggests a strong buy, with an average target price of $45.78.

About Septerna, Inc.

Septerna, Inc. is a biotechnology company based in South San Francisco, California. Founded in 2019, it focuses on developing oral small molecule therapies targeting G protein-coupled receptors for various diseases, including endocrinology, immunology, and metabolic conditions. The company collaborates with Novo Nordisk to advance several potential therapies. Under the leadership of CEO Dr. Jeffrey T. Finer, Septerna employs about 130 people.

Bottom Line

Bernard Coulie's recent purchase of Septerna, Inc. shares highlights insider confidence in the company's future. Investors often watch such moves for potential insights into the company's prospects. While 13F filings and insider transactions are backward-looking, they provide a window into the strategic decisions of those closely involved with the company.